“These measures to restrict the use of this product only within a supervised health care setting, and not for home use, are important steps to help prevent misuse and abuse,” he wrote. He also pointed to the agency’s new powers to require post-market studies evaluating the efficacy of opioid medications that the F.D.A. might be having second thoughts about, and to consider abuse risk as a factor in making regulatory decisions about drugs after, as well as before, they’re on the market. asked the maker of Opana ER, another super-potent opioid, to take it off the market because of concerns about abuse. had approved for Dsuvia, including monitoring distribution of the drug and auditing wholesalers’ data; evaluating whether hospitals and other health care providers are using the drug properly; and monitoring for any diversion or abuse.

Source: New York Times November 02, 2018 21:45 UTC